After 30 years, Griffin to retire from Raven board

Lewis Drug CEO Mark Griffin has served on the board of Raven Industries Inc. for three decades but is retiring from it to focus on other commitments.

“I’m honored to have served on the Raven board for 30 years,” he said.

“Watching the company grow and establish itself as an innovative, service-driven technology company has truly been a fulfilling experience. While I’m stepping down to concentrate on my business, Lewis Drug, and to serve on several drugstore industry boards, I believe Raven is well-positioned for success in the years to come.”

Griffin’s retirement will be effective Dec. 4.

“We thank Mark for his wise counsel and many contributions over the last several years,” Raven president and CEO Dan Rykhus said. “He has represented our shareholders well, and we will miss his leadership and perspective.”

The board plans to select a replacement in the coming weeks.

“Raven has benefited greatly from Mark’s leadership and guidance during his tenure on the board of directors,” said Marc LeBaron, Raven’s chairman of the board. “His business acumen, along with his deep understanding of the Raven culture, has been invaluable.”

Family ties to Raven run deep, Griffin added. His father, John, served on the board of directors as well, giving the family a combined half-century of service.

After 30 years, Griffin to retire from Raven board

Lewis Drug CEO Mark Griffin has served on the board of Raven Industries Inc. for three decades but is retiring from it to focus on other commitments.

News Tip

Have a business news item to share with us?

Scroll to top